Menu Menu


GSK Financials       Clear


GSK        0001131399    
Filing Date Form Type Description Document
2025-04-30 6-K TRANSACTION IN OWN SHARES View Document
2025-04-30 6-K 1ST QUARTER RESULTS View Document
2025-04-29 6-K TRANSACTION IN OWN SHARES View Document
2025-04-28 6-K TRANSACTION IN OWN SHARES View Document
2025-04-25 6-K TRANSACTION IN OWN SHARES View Document
2025-04-24 6-K TRANSACTION IN OWN SHARES View Document
2025-04-23 6-K TRANSACTION IN OWN SHARES View Document
2025-04-22 6-K TRANSACTION IN OWN SHARES View Document
2025-04-17 6-K BLENREP LICENSED BY UK MHRA View Document
2025-04-17 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-04-17 6-K AREXVY NOW ACIP RECOMMENDED FOR 50-59 AT RIS View Document
2025-04-17 6-K GSK 5-IN-1 MENINGITIS VACCINE RECOMMENDED IN US View Document
2025-04-17 6-K TRANSACTION IN OWN SHARES View Document
2025-04-16 6-K TRANSACTION IN OWN SHARES View Document
2025-04-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-04-15 6-K TRANSACTION IN OWN SHARES View Document
2025-04-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-04-14 6-K TRANSACTION IN OWN SHARES View Document
2025-04-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-04-11 6-K TRANSACTION IN OWN SHARES View Document
2025-04-10 6-K TRANSACTION IN OWN SHARES View Document
2025-04-09 6-K TRANSACTION IN OWN SHARES View Document
2025-04-08 6-K TRANSACTION IN OWN SHARES View Document
2025-04-07 6-K TRANSACTION IN OWN SHARES View Document
2025-04-04 6-K TRANSACTION IN OWN SHARES View Document
2025-04-03 6-K TRANSACTION IN OWN SHARES View Document
2025-04-02 6-K TRANSACTION IN OWN SHARES View Document
2025-04-01 6-K TOTAL VOTING RIGHTS View Document
2025-04-01 6-K TRANSACTION IN OWN SHARES View Document
2025-03-31 6-K TRANSACTION IN OWN SHARES View Document
2025-03-28 SCHEDULE 13D/A View Document
2025-03-28 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-03-28 6-K TRANSACTION IN OWN SHARES View Document
2025-03-27 6-K TRANSACTION IN OWN SHARES View Document
2025-03-26 6-K TRANSACTION IN OWN SHARES View Document
2025-03-25 6-K GSK UUTI TREATMENT APPROVED BY US FDA View Document
2025-03-25 6-K TRANSACTION IN OWN SHARES View Document
2025-03-24 6-K NOTICE OF AGM View Document
2025-03-24 6-K EMA FILING ACCEPTANCE FOR NUCALA COPD View Document
2025-03-24 6-K TRANSACTION IN OWN SHARES View Document
2025-03-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-03-21 6-K TRANSACTION IN OWN SHARES View Document
2025-03-20 6-K TRANSACTION IN OWN SHARES View Document
2025-03-19 6-K TRANSACTION IN OWN SHARES View Document
2025-03-18 CERT NYSE CERTIFICATION View Document
2025-03-18 CERT NYSE CERTIFICATION View Document
2025-03-18 6-K TRANSACTION IN OWN SHARES View Document
2025-03-17 6-K TRANSACTION IN OWN SHARES View Document
2025-03-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-03-14 6-K TRANSACTION IN OWN SHARES View Document
2025-03-13 8-A12B 8-A12B View Document
2025-03-13 8-A12B 8-A12B View Document
2025-03-13 6-K 6-K View Document
2025-03-13 6-K TRANSACTION IN OWN SHARES View Document
2025-03-12 6-K TRANSACTION IN OWN SHARES View Document
2025-03-11 6-K TRANSACTION IN OWN SHARES View Document
2025-03-10 424B2 424B2 View Document
2025-03-10 6-K TRANSACTION IN OWN SHARES View Document
2025-03-07 SCHEDULE 13G/A View Document
2025-03-07 6-K TRANSACTION IN OWN SHARES View Document
2025-03-07 FWP FWP View Document
2025-03-06 424B2 424B2 View Document
2025-03-06 6-K TRANSACTION IN OWN SHARES View Document
2025-03-05 6-K TRANSACTION IN OWN SHARES View Document
2025-03-04 6-K TRANSACTION IN OWN SHARES View Document
2025-03-03 6-K GSK PLC 2024 ANNUAL REPORT ON FORM 20-F View Document
2025-03-03 IRANNOTICE IRANNOTICE View Document
2025-03-03 20-F 20-F View Document
2025-03-03 6-K TOTAL VOTING RIGHTS View Document
2025-03-03 6-K US FDA ACCEPT 2 DEPEMOKIMAB INDICATION SUBMISSIONS View Document
2025-03-03 6-K ANCHOR RESULTS PRESENTED AT 2025 AAAAI View Document
2025-03-03 6-K TRANSACTION IN OWN SHARES View Document
2025-02-28 6-K TRANSACTION IN OWN SHARES View Document
2025-02-27 6-K TRANSACTION IN OWN SHARES View Document
2025-02-27 6-K GSK PUBLISHES ANNUAL REPORT 2024 View Document
2025-02-26 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-02-26 6-K TRANSACTION IN OWN SHARES View Document
2025-02-25 6-K TRANSACTION IN OWN SHARES View Document
2025-02-24 6-K GSK COMPLETES ACQUISITION OF IDRX, INC. View Document
2025-02-24 6-K GSK PLC COMMENCES SHARE BUYBACK PROGRAMME View Document
2025-02-21 6-K DIRECTORATE CHANGE View Document
2025-02-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-02-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-02-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-02-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-02-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-02-21 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-02-20 6-K NUCALA COPD SUBMISSION ACCEPTED IN CHINA View Document
2025-02-18 6-K GSK 5-IN-1 MENINGITIS VACCINE APPROVED BY US FDA View Document
2025-02-13 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-02-11 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-02-05 6-K FINAL RESULTS View Document
2025-02-03 6-K TOTAL VOTING RIGHTS View Document
2025-01-28 6-K DEPEMOKIMAB DUAL FILING IN CHINA AND JAPAN View Document
2025-01-28 6-K EMA ACCEPTS TWO SUBMISSIONS FOR DEPEMOKIMAB View Document
2025-01-27 6-K EMA ACCEPT REVIEW SHINGRIX SYRINGE PRESENTATION View Document
2025-01-21 6-K JEMPERLI EXPANDED APPROVAL IN THE EU View Document
2025-01-16 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-01-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2025-01-14 6-K DIRECTOR/PDMR SHAREHOLDING View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299